Chester County News and Community Website
HORSHAM, PA — In a significant medical breakthrough, Johnson & Johnson recently announced FDA’s approval of CARVYKTI® for the treatment of adult patients with multiple myeloma. This approval marks a …
FDA Approves Johnson & Johnson’s Innovative, Immuno-Targeted Multiple Myeloma Therapy, CARVYKTI Read More
NEWTOWN SQUARE, PA — In recent developments from the pharmaceutical industry, ArriVent BioPharma Inc. (Nasdaq: AVBP), a notable player in the arena of breakthrough cancer therapy, has seen a transformative …
ArriVent BioPharma Unveils Promising Developments and Strong Financial Performance in 2023 Read More
PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …
Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More
PHILADELPHIA, PA — The biotech firm Cabaletta Bio, Inc. (Nasdaq: CABA) has secured an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its investigational therapy, …
FDA Awards Orphan Drug Designation to Cabaletta’s Innovative Myositis Therapy Read More
WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …
Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More
The U.S. Food and Drug Administration (FDA) recently approved Ogsiveo (nirogacestat) tablets for the systemic treatment of adult patients with progressing desmoid tumors, marking it as the first drug to …
FDA Approves Ogsiveo, First-Ever Drug for Treatment of Desmoid Tumors Read More
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) announced that the U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to its lead clinical candidate TI-168 for the …
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Galera’s second product candidate, rucosopasem manganese (rucosopasem), …
Galera’s Second Candidate Granted Orphan Drug Designation for Pancreatic Cancer Treatment Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA recently granted Orphan Drug Designation for its OCU410ST (AAV5-hRORA), an adeno-associated virus serotype 5 capsid protein containing gene construct …
Ocugen Announces OCU410ST Receives Orphan Drug Designation Read More
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the U.S. Food and Drug Administration (FDA) recently granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut …
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read More